RBFC
BMY icon

Roman Butler Fullerton & Co’s Bristol-Myers Squibb BMY Stock Holding History

Roman Butler Fullerton & Co’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.39M Buy
23,488
+1,464
+7% +$85.3K 0.38% 66
2025
Q4 		$1.21M Buy
22,024
+7,720
+54% +$371K 0.32% 82
2025
Q3 		$609K Buy
14,304
+25
+0.2% +$1.17K 0.16% 137
2025
Q2 		$692K Sell
14,279
-5,899
-29% -$290K 0.2% 122
2025
Q1 		$1.01M Buy
20,178
+1,482
+8% +$86.4K 0.39% 62
2024
Q4 		$1.13M Buy
18,696
+4,718
+34% +$264K 0.36% 73
2024
Q3 		$737K Buy
13,978
+650
+5% +$30.5K 0.22% 105
2024
Q2 		$548K Sell
13,328
-1,810
-12% -$81K 0.18% 123
2024
Q1 		$744K Sell
15,138
-2,291
-13% -$117K 0.28% 89
2023
Q4 		$866K Sell
17,429
-1,652
-9% -$86.7K 0.34% 77
2023
Q3 		$1.08M Hold
19,081
– – 0.51% 59
2023
Q2 		$1.18M Sell
19,081
-1,915
-9% -$128K 0.54% 54
2023
Q1 		$1.47M Buy
20,996
+762
+4% +$53.7K 0.73% 33
2022
Q4 		$1.46M Sell
20,234
-56
-0.3% -$4.22K 0.76% 36
2022
Q3 		$1.41M Buy
20,290
+96
+0.5% +$6.96K 0.9% 26
2022
Q2 		$1.53M Buy
20,194
+42
+0.2% +$3.2K 0.85% 29
2022
Q1 		$1.47M Sell
20,152
-607
-3% -$40.8K 0.68% 38
2021
Q4 		$1.29M Sell
20,759
-89
-0.4% -$5.22K 0.57% 55
2021
Q3 		$1.19M Buy
20,848
+3,130
+18% +$206K 0.55% 60
2021
Q2 		$1.18M Buy
17,718
+99
+0.6% +$6.46K 0.58% 56
2021
Q1 		$1.14M Sell
17,619
-15
-0.1% -$933 0.57% 56
2020
Q4 		$1.09M Buy
17,634
+99
+0.6% +$6.09K 0.65% 51
2020
Q3 		$1.06M Sell
17,535
-543
-3% -$32.7K 0.69% 46
2020
Q2 		$1.06M Sell
18,078
-24
-0.1% -$1.44K 0.76% 42
2020
Q1 		$1.01M Sell
18,102
-210
-1% -$12.8K 0.89% 32
2019
Q4 		$1.18M Buy
18,312
+289
+2% +$16.6K 0.78% 34
2019
Q3 		$914K Buy
18,023
+120
+0.7% +$5.64K 0.63% 50
2019
Q2 		$812K Sell
17,903
-127
-0.7% -$5.92K 0.55% 57
2019
Q1 		$860K Buy
18,030
+244
+1% +$12.2K 0.6% 53
2018
Q4 		$849K Buy
+17,786
New +$956K 0.72% 46

Other funds holding BMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Roman Butler Fullerton & Co's BMY Position: Q1 2026 in Review

Roman Butler Fullerton & Co increased its Bristol-Myers Squibb (BMY) stake by 6.6% in Q1 2026, buying an estimated $85.3K and bringing the position to 23,488 shares worth $1.39M. The position accounts for 0.38% of the portfolio, ranked #66.

Roman Butler Fullerton & Co first reported a position in BMY in Q4 2018 and has held it in 30 quarters since. The position peaked at $1.53M in Q2 2022. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Roman Butler Fullerton & Co held 23,488 shares of Bristol-Myers Squibb worth $1.39M as of Q1 2026.
  • Roman Butler Fullerton & Co bought 1,464 Bristol-Myers Squibb shares in Q1 2026, an estimated $85.3K.
  • Bristol-Myers Squibb made up 0.38% of Roman Butler Fullerton & Co's portfolio in Q1 2026, its #66 holding.
  • Roman Butler Fullerton & Co first reported a position in Bristol-Myers Squibb in Q4 2018 and has held it in 30 quarters since.
  • Roman Butler Fullerton & Co's Bristol-Myers Squibb position peaked at $1.53M in Q2 2022.
  • 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Roman Butler Fullerton & Co's 13F filing for Q1 2026, filed 30 Apr 2026.